{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:41:38Z","timestamp":1780555298679,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.cllc.2024.09.002","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T15:58:23Z","timestamp":1726847903000},"page":"152-157.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Na\u00efve NSCLC Patients Harboring EGFR 21L858R Mutation"],"prefix":"10.1016","volume":"26","author":[{"given":"Qing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Dong","family":"Cang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Wen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Tao","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Qiu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3837-0758","authenticated-orcid":false,"given":"Si-Yang Maggie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cllc.2024.09.002_bib0001","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","article-title":"The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics","volume":"11","author":"Cheng","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2024.09.002_bib0002","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.cllc.2024.09.002_bib0003","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"10.1016\/j.cllc.2024.09.002_bib0004","first-page":"270","article-title":"Lung cancer molecular epidemiology in China: recent trends","volume":"3","author":"Zhou","year":"2014","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"10.1016\/j.cllc.2024.09.002_bib0005","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.09.002_bib0006","series-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2017"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.002_bib0007","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0003-4975(96)00220-2","article-title":"Distribution of distant metastases from newly diagnosed non-small cell lung cancer","volume":"62","author":"Quint","year":"1996","journal-title":"Ann Thorac Surg"},{"issue":"19","key":"10.1016\/j.cllc.2024.09.002_bib0008","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cllc.2024.09.002_bib0009","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2015.4482","article-title":"Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"10026","key":"10.1016\/j.cllc.2024.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.cllc.2024.09.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143515","article-title":"Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - mainland China subset analysis of the PIONEER study","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2024.09.002_bib0012","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"10.1016\/j.cllc.2024.09.002_bib0013","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2024.09.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9005","article-title":"CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3)","author":"Mok","year":"2017","journal-title":"J Clin Oncol."},{"issue":"13","key":"10.1016\/j.cllc.2024.09.002_bib0015","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","article-title":"Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib","volume":"12","author":"Jackman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2024.09.002_bib0016","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/CMAR.S138643","article-title":"Comparison of gefitinib as first- and secondline therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation","volume":"9","author":"Patel","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"27","key":"10.1016\/j.cllc.2024.09.002_bib0017","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2024.09.002_bib0018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.09.002_bib0019","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.cllc.2024.09.002_bib0020","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized Phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or MetastaticNon-Small-Cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.cllc.2024.09.002_bib0021","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cllc.2024.09.002_bib0022","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/sj.bjc.6601005","article-title":"Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11","volume":"88","author":"Wildiers","year":"2003","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1016\/j.cllc.2024.09.002_bib0023","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","article-title":"Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy","volume":"13","author":"Dickson","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.cllc.2024.09.002_bib0024","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1056\/NEJMcibr0902054","article-title":"A new target for tumor therapy","volume":"360","author":"Jain","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2024.09.002_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2024.09.002_bib0026","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.cllc.2024.09.002_bib0027","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2024.09.002_bib0028","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2024.09.002_bib0029","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamaoncol.2020.1260","article-title":"Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR -mutant lung cancers: a phase 1\/2 single-group open-label trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2024.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2024.09.002_bib0031","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.cllc.2024.09.002_bib0032","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.canlet.2008.02.064","article-title":"Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals","volume":"265","author":"quan","year":"2008","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.cllc.2024.09.002_bib0033","first-page":"3887","article-title":"Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer","volume":"18","author":"Hong","year":"2019","journal-title":"Oncol Lett"},{"issue":"5","key":"10.1016\/j.cllc.2024.09.002_bib0034","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2018.0049","article-title":"Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-Mutant advanced non\u2013small cell lung cancer","volume":"4","author":"Hong","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2024.09.002_bib0035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jtho.2016.09.001","article-title":"EGFR-Co-mutated advanced NSCLC and response to EGFR tyrosine kinase inhibitors","volume":"12","author":"Barnet","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2024.09.002_bib0036","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jtho.2020.08.020","article-title":"Refined stratification based on baseline concomitant mutations and longitudinal circulating tumor DNA monitoring in advanced EGFR-mutant lung adenocarcinoma under gefitinib treatment","volume":"15","author":"Duan","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2024.09.002_bib0037","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.21037\/jtd.2019.11.04","article-title":"The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base","volume":"11","author":"Jiao","year":"2019","journal-title":"J Thorac Dis"},{"issue":"12","key":"10.1016\/j.cllc.2024.09.002_bib0038","first-page":"3402","article-title":"A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis","volume":"62","author":"Casanova","year":"2002","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.cllc.2024.09.002_bib0039","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cell.2009.12.046","article-title":"Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development","volume":"140","author":"Lichtenberger","year":"2010","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.cllc.2024.09.002_bib0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.lungcan.2008.03.011","article-title":"Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients","volume":"62","author":"Reinmuth","year":"2008","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2024.09.002_bib0041","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.cllc.2021.10.007","article-title":"Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non\u2013small cell lung cancer positive for the L858R mutation of EGFR: REVOL858R (WJOG14420L)","volume":"23","author":"Haratake","year":"2022","journal-title":"Clin Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T12:34:37Z","timestamp":1739018077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424001992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1525730424001992"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.09.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Na\u00efve NSCLC Patients Harboring EGFR 21L858R Mutation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}